Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

EOCN holding history

Galmed Pharmaceuticals Ltd. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

EOCN overviewAll 13F holders of EOCNFull Q2 2026 holdings

Shares (Q2 2026)
3
Value
$2
% of portfolio
<0.1%
Quarters held
19
Since Q1 2021
Holdings of EOCN by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20263$2<0.1%−2,543−99.9%ReducedHolders
Q1 20262,546$1.25K<0.1%+732+40.4%AddedHolders
Q4 20251,814$1.36K<0.1%+851+88.4%AddedHolders
Q3 2025963$1.33K<0.1%−5,940−86.0%ReducedHolders
Q2 20256,903$12.7K<0.1%+5,799+525.3%AddedHolders
Q1 20251,104$1.59K<0.1%−5,617−83.6%ReducedHolders
Q4 20246,721$21.4K<0.1%+1,454+27.6%AddedHolders
Q3 20245,267$36.1K<0.1%+4,987+1,781.1%AddedHolders
Q2 2024280$77<0.1%−1,980−87.6%ReducedHolders
Q1 20242,260$782<0.1%+2,260NewHolders
Q4 20230$00.0%−28−100.0%Sold outHolders
Q3 202328$17<0.1%+27+2,700.0%AddedHolders
Q2 20231$3<0.1%−286−99.7%ReducedConverted for a 1-for-15 splitHolders
Q1 20234,307$1.83K<0.1%−17,125−79.9%ReducedHolders
Q4 202221,432$10.7K<0.1%−5,554−20.6%ReducedHolders
Q3 202226,986$8.00K<0.1%+20,922+345.0%AddedHolders
Q2 20226,064$4.00K<0.1%+6,064NewHolders
Q1 20220$00.0%−6,356−100.0%Sold outHolders
Q4 20216,356$12.0K<0.1%+6,196+3,872.5%AddedHolders
Q3 2021160$00.0%+160NewHolders
Q2 20210$00.0%−3,418−100.0%Sold outHolders
Q1 20213,418$12.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.